Stonepine Capital, L.P. Purchases 22,845 Shares of Apollo Endosurgery Inc (APEN) Stock
Apollo Endosurgery Inc (NASDAQ:APEN) major shareholder Stonepine Capital, L.P. bought 22,845 shares of the stock in a transaction that occurred on Wednesday, January 3rd. The shares were bought at an average cost of $5.71 per share, with a total value of $130,444.95. Following the completion of the transaction, the insider now owns 2,560,314 shares in the company, valued at $14,619,392.94. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Major shareholders that own at least 10% of a company’s shares are required to disclose their sales and purchases with the SEC.
Stonepine Capital, L.P. also recently made the following trade(s):
- On Saturday, December 29th, Stonepine Capital, L.P. bought 5,163 shares of Apollo Endosurgery stock. The shares were bought at an average cost of $5.56 per share, with a total value of $28,706.28.
- On Tuesday, December 26th, Stonepine Capital, L.P. bought 5,287 shares of Apollo Endosurgery stock. The shares were bought at an average cost of $5.00 per share, with a total value of $26,435.00.
- On Wednesday, December 20th, Stonepine Capital, L.P. acquired 45,434 shares of Apollo Endosurgery stock. The stock was acquired at an average cost of $4.50 per share, with a total value of $204,453.00.
- On Friday, December 22nd, Stonepine Capital, L.P. acquired 185,157 shares of Apollo Endosurgery stock. The stock was acquired at an average cost of $4.85 per share, with a total value of $898,011.45.
Apollo Endosurgery Inc (APEN) traded down $0.07 during mid-day trading on Wednesday, hitting $5.82. The stock had a trading volume of 66,758 shares, compared to its average volume of 76,200. Apollo Endosurgery Inc has a 1 year low of $3.55 and a 1 year high of $19.95. The company has a debt-to-equity ratio of 0.58, a quick ratio of 2.00 and a current ratio of 2.54. The company has a market cap of $100.63, a price-to-earnings ratio of -0.27 and a beta of 0.44.
APEN has been the subject of several research analyst reports. Northland Securities reissued a “buy” rating on shares of Apollo Endosurgery in a research report on Friday, October 27th. Zacks Investment Research raised Apollo Endosurgery from a “hold” rating to a “buy” rating and set a $4.75 price objective for the company in a research report on Thursday, November 2nd. Finally, ValuEngine raised Apollo Endosurgery from a “strong sell” rating to a “sell” rating in a research report on Wednesday. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and three have given a buy rating to the stock. The stock presently has an average rating of “Hold” and an average target price of $9.44.
About Apollo Endosurgery
Apollo Endosurgery, Inc, formerly Lpath, Inc, is a medical device company. The Company is focused on less invasive therapies for the treatment of obesity, as well as other gastrointestinal disorders. The Company’s device-based therapies are an alternative to invasive surgical procedures. The Company offers products in over 80 countries.
Receive News & Ratings for Apollo Endosurgery Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Apollo Endosurgery and related companies with MarketBeat.com's FREE daily email newsletter.